STATE-OF-THE-ART PAPER
Use of ultrasound contrast agents for gene or drug delivery in cardiovascular medicine
Raffi Bekeredjian, MD*,
Paul A. Grayburn, MD, FACC ,* and
Ralph V. Shohet, MD*
* Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas
Baylor University Medical Center, Dallas, Texas
Manuscript received July 2, 2004;
revised manuscript received August 16, 2004,
accepted August 17, 2004.
* Reprint requests and correspondence: Dr. Paul A. Grayburn, Baylor Heart and Vascular Institute, 621 N. Hall Street, Suite H030, Dallas, Texas 75226 (Email: paulgr{at}baylorhealth.edu).
The clinical utility of ultrasound contrast agents has been established in diagnostic echocardiography. Recently, the use of such agents has been promoted for transport and delivery of various bioactive substances, thus providing a technique for non-invasive gene therapy and organ-specific drug delivery. In this review, we give a critical update of published studies using ultrasound contrast agents for therapeutic use. We discuss the potential applications and limitations of this technique and suggest future applications in cardiovascular medicine.
|
Abbreviations and Acronyms
| | DNA = deoxyribonucleic acid | | GFP = green fluorescent protein | | UTMD = ultrasound-targeted microbubble destruction | | VEGF = vascular endothelial growth factor |
|
This article has been cited by other articles:

|
 |

|
 |
 
K. G. Barringhaus and P. D. Zamore
MicroRNAs: Regulating a Change of Heart
Circulation,
April 28, 2009;
119(16):
2217 - 2224.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Takahashi and H. Matsubara
New Targeted Angiogenic Strategy: Bursting Bubbles
Circ. Res.,
August 3, 2007;
101(3):
232 - 233.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Leong-Poi, M. A. Kuliszewski, M. Lekas, M. Sibbald, K. Teichert-Kuliszewska, A. L. Klibanov, D. J. Stewart, and J. R. Lindner
Therapeutic Arteriogenesis by Ultrasound-Mediated VEGF165 Plasmid Gene Delivery to Chronically Ischemic Skeletal Muscle
Circ. Res.,
August 3, 2007;
101(3):
295 - 303.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. T.W. Moonen
Spatio-Temporal Control of Gene Expression and Cancer Treatment Using Magnetic Resonance Imaging-Guided Focused Ultrasound
Clin. Cancer Res.,
June 15, 2007;
13(12):
3482 - 3489.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Van Camp, S. Droogmans, and B. Cosyns
Bio-effects of ultrasound contrast agents in daily clinical practice: fact or fiction?
Eur. Heart J.,
May 2, 2007;
28(10):
1190 - 1192.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Chen, J.-h. Ding, R. Bekeredjian, B.-z. Yang, R. V. Shohet, S. A. Johnston, H. E. Hohmeier, C. B. Newgard, and P. A. Grayburn
Efficient gene delivery to pancreatic islets with ultrasonic microbubble destruction technology
PNAS,
May 30, 2006;
103(22):
8469 - 8474.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. V. Shohet and P. A. Grayburn
Potential Bioeffects of Ultrasonic Destruction of Microbubble Contrast Agents
J. Am. Coll. Cardiol.,
April 4, 2006;
47(7):
1469 - 1470.
[Full Text]
[PDF]
|
 |
|
|